HSIEN-YI CHIUCheng Y.P.SHIOU-HWA JEETSEN-FANG TSAI2022-01-112022-01-1120120307-6938https://www.scopus.com/inward/record.uri?eid=2-s2.0-84870066461&doi=10.1111%2fj.1365-2230.2012.04415.x&partnerID=40&md5=805f10f7ae919618e8b20a17720c5a77https://scholars.lib.ntu.edu.tw/handle/123456789/592101[SDGs]SDG3cisplatin; desoximetasone; dexamethasone; docetaxel; erlotinib; etoposide; gemcitabine; paclitaxel; pemetrexed; tetracycline; adult; cancer combination chemotherapy; cancer radiotherapy; case report; coughing; disease course; disease severity; drug eruption; drug withdrawal; eczema; epiluminescence microscopy; human; letter; leukocytoclastic vasculitis; lung adenocarcinoma; male; outcome assessment; paronychia; physical examination; pleura effusion; priority journal; radiation dose fractionation; treatment duration; Adenocarcinoma; Combined Modality Therapy; Drug Eruptions; Eczema; Exanthema; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolinesletter10.1111/j.1365-2230.2012.04415.x227317952-s2.0-84870066461